Mucinous Cystadenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MCN008 MIFTS: 43	Mucinous Cystadenocarcinoma Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Mucinous Cystadenocarcinoma

MalaCards integrated aliases for Mucinous Cystadenocarcinoma:

Name: Mucinous Cystadenocarcinoma ¹² ¹⁵

Cystadenocarcinoma, Mucinous ⁴⁴ ⁷³

Pseudomucinous Cystadenocarcinoma ¹²

Cystadenocarcinoma Mucinous ⁵⁵

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3603

MeSH ⁴⁴ D018282

NCIt ⁵⁰ C3776

SNOMED-CT ⁶⁸ 79143006

UMLS ⁷³ C0206699

Sources

Summaries for Mucinous Cystadenocarcinoma

Disease Ontology : ¹² A cystadenocarcinoma that derives from epithelial cells originating in glandular tissue, with a capsulated structure and mucus-producing cells.

MalaCards based summary : Mucinous Cystadenocarcinoma, also known as cystadenocarcinoma, mucinous, is related to ovarian mucinous cystadenocarcinoma and cystadenocarcinoma. An important gene associated with Mucinous Cystadenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and O-linked glycosylation. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and appendix, and related phenotype is Reduced mammosphere formation.

Wikipedia : ⁷⁶ Mucinous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma... more...

Sources

Related Diseases for Mucinous Cystadenocarcinoma

Diseases related to Mucinous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)

#	Related Disease	Score	Top Affiliating Genes
1	ovarian mucinous cystadenocarcinoma	33.7	FSHR PCNA VIM
2	cystadenocarcinoma	31.6	KRT7 MUC1 MUC16 MUC2
3	giant cell tumor	30.7	MUC1 PTPRC VIM
4	krukenberg carcinoma	30.4	KRT20 KRT7
5	cystic teratoma	30.4	KRT20 KRT7 MUC2
6	pseudomyxoma peritonei	30.4	KRT20 KRT7 MUC1 MUC2
7	endodermal sinus tumor	30.2	MUC16 VIM
8	mucinous ovarian cystadenoma	30.1	KRT7 MUC1
9	cystadenoma	30.0	KRT20 KRT7 MUC1 MUC2
10	ovarian brenner tumor	30.0	KRT20 KRT7 MUC16
11	small cell carcinoma	29.8	KRT20 KRT7 PTPRC
12	dermoid cyst	29.7	KRT20 KRT7 MUC1 VIM
13	ovarian cancer	29.4	FSHR KRT7 MUC1 MUC16 MUC2
14	lung mucinous cystadenocarcinoma	12.5
15	mucinous cystadenocarcinoma of the pancreas	12.4
16	appendix mucinous cystadenocarcinoma	12.2
17	breast mucinous cystadenocarcinoma	12.2
18	pancreatic non-invasive mucinous cystadenocarcinoma	12.2
19	pancreatic invasive mucinous cystadenocarcinoma	12.2
20	pancreatic colloid cystadenocarcinoma	11.2
21	gelatinous ascites	10.5
22	teratoma	10.4
23	sarcoma	10.4
24	hemangiopericytoma, malignant	10.3	MUC1 VIM
25	osteofibrous dysplasia	10.3	MUC1 VIM
26	chondroid chordoma	10.3	MUC1 VIM
27	perineurioma	10.3	MUC1 VIM
28	optic nerve glioma	10.3	MUC1 VIM
29	cerebral primitive neuroectodermal tumor	10.3	MUC1 VIM
30	fasciitis	10.3	MUC1 VIM
31	polymorphous low-grade adenocarcinoma	10.3	MUC1 VIM
32	myoepithelioma	10.3	PTPRC VIM
33	reticulosarcoma	10.3	MUC1 PTPRC
34	plasmablastic lymphoma	10.3	MUC1 PTPRC
35	fibrolamellar carcinoma	10.3	KRT7 VIM
36	granulosa cell tumor of the ovary	10.3	KRT7 VIM
37	pulmonary hemosiderosis	10.2	KRT7 MUC1
38	malignant ovarian surface epithelial-stromal neoplasm	10.2	KRT7 MUC1
39	ovary epithelial cancer	10.2	KRT7 MUC1
40	sertoli-leydig cell tumor	10.2	KRT7 MUC1
41	intraneural perineurioma	10.2	KRT7 MUC1
42	sclerosing hemangioma	10.2	KRT7 MUC1
43	lipoadenoma	10.2	KRT7 MUC1
44	syringoma	10.2	MUC1 VIM
45	malignant peritoneal mesothelioma	10.2	MUC1 VIM
46	primitive neuroectodermal tumor of the cervix uteri	10.2	PTPRC VIM
47	papillary tumor of the pineal region	10.2	MUC1 VIM
48	syringocystadenoma papilliferum	10.2	MUC1 VIM
49	ossifying fibromyxoid tumor	10.2	MUC1 VIM
50	multicentric reticulohistiocytosis	10.2	PTPRC VIM

Graphical network of the top 20 diseases related to Mucinous Cystadenocarcinoma:

Sources

Symptoms & Phenotypes for Mucinous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.02	FSHR KRT7 PCNA PTPRC VIM

Sources

Drugs & Therapeutics for Mucinous Cystadenocarcinoma

Drugs for Mucinous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

41575-94-4

10339178 38904 498142

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

33069-62-4

36314

Bevacizumab

Approved, Investigational

Phase 3,Phase 1

216974-75-3

Cisplatin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

2767 441203 84093

Cyclophosphamide

Approved, Investigational

Phase 3,Phase 2,Phase 1

6055-19-2, 50-18-0

2907

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 3,Phase 1

61825-94-3

43805 6857599 5310940 9887054

Mitoxantrone

Approved, Investigational

Phase 3

65271-80-9

4212

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Not Applicable

59-30-3

6037

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1,Not Applicable

Antimitotic Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1,Not Applicable

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 1

Angiogenesis Modulating Agents

Phase 3,Phase 1

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Alkylating

Phase 3,Phase 2,Phase 1

Antirheumatic Agents

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Alkylating Agents

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Immunoglobulin G

Phase 3,Phase 1

Endothelial Growth Factors

Phase 3,Phase 1

Mitogens

Phase 3,Phase 1

Peripheral Nervous System Agents

Phase 3,Phase 1,Not Applicable

Analgesics

Phase 3,Phase 1

Micronutrients

Phase 3,Not Applicable

Vitamin B9

Phase 3,Not Applicable

Vitamins

Phase 3,Not Applicable

Trace Elements

Phase 3,Not Applicable

Folate

Phase 3,Not Applicable

Vitamin B Complex

Phase 3,Not Applicable

Doxorubicin

Approved, Investigational

Phase 2,Phase 1

23214-92-8

31703

Belinostat

Approved, Investigational

Phase 2

866323-14-0

Docetaxel

Approved, Investigational

Phase 1, Phase 2,Phase 2

114977-28-5

148124

Topotecan

Approved, Investigational

Phase 2,Phase 1

123948-87-8, 119413-54-6

60700

Lenograstim

Approved, Investigational

Phase 2,Phase 1

135968-09-1

Nivolumab

Approved

Phase 2

946414-94-4

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Doxil

Approved June 1999

Phase 2,Phase 1

31703

Antibiotics, Antitubercular

Phase 2,Phase 1

Anti-Bacterial Agents

Phase 2,Phase 1

Histone Deacetylase Inhibitors

Phase 2

Protein Kinase Inhibitors

Phase 2,Phase 1

Erlotinib Hydrochloride

Phase 2,Phase 1

183319-69-9

176871

topoisomerase I inhibitors

Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 58)

#	Name	Status	NCT ID	Phase	Drugs
1	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	Completed	NCT00483782	Phase 3	carboplatin;paclitaxel
2	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer	Completed	NCT00002568	Phase 3	cisplatin;paclitaxel
3	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer	Completed	NCT00002717	Phase 3	cisplatin;paclitaxel
4	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer	Completed	NCT00003322	Phase 3	cisplatin;paclitaxel
5	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer	Completed	NCT00003644	Phase 3	carboplatin;paclitaxel
6	Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer	Active, not recruiting	NCT01081262	Phase 3	Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
7	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Active, not recruiting	NCT00951496	Phase 3	Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
8	Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer	Terminated	NCT00003880	Phase 2, Phase 3	carboplatin;paclitaxel
9	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer	Terminated	NCT00002819	Phase 3	carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
10	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy	Withdrawn	NCT01492920	Phase 3
11	VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Unknown status	NCT01666444	Phase 2	pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
12	Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer	Unknown status	NCT00017303	Phase 2	carboplatin;oglufanide disodium;paclitaxel
13	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin	Completed	NCT00993616	Phase 2	belinostat;carboplatin
14	A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Completed	NCT00939809	Phase 2
15	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy	Completed	NCT00466960	Phase 2	paclitaxel albumin-stabilized nanoparticle formulation
16	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma	Completed	NCT00059787	Phase 2	paclitaxel;carboplatin;erlotinib
17	S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer	Completed	NCT00008138	Phase 2	carboplatin;paclitaxel
18	Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer	Completed	NCT00217529	Phase 1, Phase 2	carboplatin;docetaxel;erlotinib hydrochloride
19	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT00003944	Phase 2	carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
20	TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Completed	NCT00022347	Phase 2	canfosfamide hydrochloride
21	Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers	Completed	NCT00002538	Phase 2
22	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Recruiting	NCT02834013	Phase 2
23	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	NCT02101775	Phase 2	Adavosertib;Gemcitabine Hydrochloride
24	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer	Terminated	NCT00004221	Phase 2	Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
25	Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Terminated	NCT00331422	Phase 2	carboplatin;paclitaxel
26	Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer	Terminated	NCT00354601	Phase 2	capecitabine;docetaxel
27	TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	Completed	NCT01294293	Phase 1	TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
28	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Completed	NCT01074411	Phase 1	Bortezomib;Carboplatin
29	Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	Completed	NCT00814086	Phase 1	Paclitaxel;Cisplatin
30	Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer	Completed	NCT00002913	Phase 1	paclitaxel;cisplatin;topotecan hydrochloride
31	Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Completed	NCT00079430	Phase 1	paclitaxel;carboplatin
32	Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)	Completed	NCT00085358	Phase 1	carboplatin;paclitaxel;docetaxel
33	Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer	Completed	NCT00060359	Phase 1	Carboplatin;Paclitaxel Poliglumex
34	Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT00006235	Phase 1	carboplatin;pegylated liposomal doxorubicin hydrochloride
35	Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer	Completed	NCT00002600	Phase 1	carboplatin;cyclophosphamide
36	Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer	Completed	NCT00003967	Phase 1	etoposide;topotecan hydrochloride
37	Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer	Completed	NCT00005026	Phase 1	carboplatin;paclitaxel;topotecan hydrochloride
38	RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma	Completed	NCT00101972	Phase 1
39	Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission	Completed	NCT00002977	Phase 1	melphalan;thiotepa
40	Gene Therapy in Treating Patients With Cancer	Completed	NCT00004178	Phase 1
41	Immunotoxin Therapy in Treating Patients With Advanced Cancer	Completed	NCT00006981	Phase 1
42	Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer	Completed	NCT00003385	Phase 1	carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
43	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	Active, not recruiting	NCT02142803	Phase 1	Sapanisertib
44	Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer	Active, not recruiting	NCT00357448	Phase 1
45	Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer	Active, not recruiting	NCT00408590	Phase 1
46	Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer	Active, not recruiting	NCT00652691	Phase 1	carboplatin;cyclophosphamide;topotecan hydrochloride
47	Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm	Terminated	NCT01525706	Phase 1	Ethanol and Paclitaxel Injection
48	Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	Terminated	NCT01233505	Phase 1	veliparib;capecitabine;oxaliplatin
49	Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer	Terminated	NCT00003380	Phase 1	etoposide;pegylated liposomal doxorubicin hydrochloride
50	Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis	Unknown status	NCT02130648

Search NIH Clinical Center for Mucinous Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma, mucinous

Sources

Genetic Tests for Mucinous Cystadenocarcinoma

Sources

Anatomical Context for Mucinous Cystadenocarcinoma

MalaCards organs/tissues related to Mucinous Cystadenocarcinoma:

⁴¹

Pancreas, Ovary, Appendix, Breast, Liver, Lung, T Cells

Sources

Publications for Mucinous Cystadenocarcinoma

Articles related to Mucinous Cystadenocarcinoma:

(show top 50) (show all 260)

#	Title	Authors	Year
1	Mucinous Cystadenocarcinoma of the Breast: Report of 2 Cases Including One With Long-Term Local Recurrence. ( 29745281 )	Nayak A....Bhuiya T.A.	2018
2	Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma. ( 29780137 )	Tanaka H....Kudo M.	2018
3	Mucinous cystadenocarcinoma arising from mucinous cystadenoma of the lung: case report and review of the literature. ( 29850162 )	Moneke I....Kayser G.	2018
4	Appendiceal mucinous cystadenocarcinoma with mural nodules of anaplastic carcinoma and K-RAS mutation. ( 30289401 )	K?r G...?zen F	2018
5	Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. ( 29081926 )	Koufopoulos N....Khaldi L.	2017
6	(18)F-FDG PET/CT Imaging of Pulmonary Mucinous Cystadenocarcinoma with Signet Ring Cells. ( 28878858 )	Kalkanis A....Kalkanis D.	2017
7	Pancreatic pseudocyst or mucinous cystadenocarcinoma of pancreas? A diagnostic dilemma. ( 28396777 )	Joshi U....Basnet B.	2017
8	The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report. ( 29177806 )	Tokai H....Fujioka H.	2017
9	Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report. ( 28449606 )		2017
10	Pulmonary Mucinous Cystadenocarcinoma Presenting as Extensive Multifocal Cystic Lesions. ( 28199793 )		2017
11	Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. ( 28976119 )		2017
12	Mucinous cystadenocarcinoma of ovary with metastasis in 14-year-old girl. ( 28344967 )		2017
13	Mucinous Cystadenocarcinoma in a Horse Shoe Kidney Masquerading as Giant Hydronephrosis - A Case Report: Diagnostic Challenges, Lessons Learnt and Review of Literature. ( 28050435 )	Joseph L.D....Sekar H.	2016
14	Giant mucinous cystadenocarcinoma of ovary: A case report and review of literature. ( 27134482 )	Katke R.D.	2016
15	A giant mucinous cystadenocarcinoma of the appendix: a case report and review of the literature. ( 26945579 )	Nagata H....Watanabe T.	2016
16	Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. ( 26681306 )	Myriokefalitaki E....Moss E.L.	2016
17	Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm. ( 27367953 )	Martingano D....Aglialoro G.	2016
18	Mature Cystic Teratoma with Co-existent Mucinous Cystadenocarcinoma in the same Ovary-A Diagnostic Dilemma. ( 28208869 )		2016
19	Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. ( 27166050 )		2016
20	Mucinous cystadenocarcinoma of the pancreas with anaplastic carcinoma: A case report and review of the literature. ( 27073646 )		2016
21	Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A Rare Case Report. ( 29927186 )		2016
22	Pancreatic mucinous cystadenocarcinoma: Epidemiology and outcomes. ( 27638187 )		2016
23	Radiologic Findings of Primary Mucinous Cystadenocarcinoma of the Breast: A Report of Two Cases and a Literature Review. ( 27721884 )	Seong M...Lee JE	2016
24	Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. ( 26259386 )	DoA9anay M....Cavkaytar S.	2015
25	A rare tumor: mucinous cystadenocarcinoma of the breast. ( 25760182 )	Witherspoon L.E....Oxenhandler R.W.	2015
26	Primary mucinous cystadenocarcinoma of the testis: An extremely rare ovarian-type surface epithelial carcinoma. ( 26458610 )	Celdran J.O....Compiano L.O.	2015
27	Primary mucinous cystadenocarcinoma of the renal pelvis misdiagnosed as ureteropelvic junction stenosis with renal pelvis stone: a case report and literature review. ( 26612470 )	Han D.S....Jang H.	2015
28	Mucinous Cystadenocarcinoma Co-Existing with Mature Cystic Teratoma : A Rare Case Report. ( 26393136 )		2015
29	Report of a case: Retroperitoneal mucinous cystadenocarcinoma with rapid progression. ( 25884614 )		2015
30	Identification of Differentially Expressed miRNAs in Appendiceal Mucinous Cystadenocarcinoma from Mucinous Cystadenoma. ( 26807210 )		2015
31	A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review. ( 25687861 )		2015
32	Mucinous cystadenocarcinoma of renal pelvis presenting as pyonephrosis. ( 24821168 )	Patel R.D....Modi P.R.	2014
33	Misdiagnosis of pancreatic papillary mucinous cystadenocarcinoma: A case report. ( 25120659 )	Qiao P.F....Gao Y.	2014
34	MRI, Enhanced CT, and FDG PET/CT in Primary Retroperitoneal Mucinous Cystadenocarcinoma. ( 24445275 )	Dong A....Zuo C.	2014
35	Primary retroperitoneal mucinous cystadenocarcinoma during pregnancy. ( 24832037 )	Hanhan H.M....A9zeren M.	2014
36	Management of a primary retroperitoneal mucinous cystadenocarcinoma: case report. ( 24772920 )	Kurita T....Hachisuga T.	2014
37	A 57-year-old Brazilian woman with a giant mucinous cystadenocarcinoma of the ovary: a case report. ( 24594205 )	de Lima S.H....Modesto F.R.	2014
38	Primary mucinous cystadenocarcinoma of the breast with amplification of the HER2 gene confirmed by FISH - case report and review of the literature. ( 25119013 )		2014
39	Port-site metastasis after explorative laparoscopy for an incidental appendiceal mucinous cystadenocarcinoma detected with FDG PET/CT. ( 23610886 )	Ceulemans G....Everaert H.	2013
40	Mucinous cystadenocarcinoma of the appendix in which contrast-enhanced ultrasonography was useful for assessing blood flow in a focal nodular lesion in the tumor cavity: A case report. ( 23935709 )	Wakui N....Kojima T.	2013
41	A case of mucinous cystadenocarcinoma of the pancreas with spontaneous rupture diagnosed by endoscopic retrograde pancreatography. ( 23526506 )	Imoto A....Higuchi K.	2013
42	Mucinous cystadenocarcinoma of the appendix mimics acute appendicitis. ( 22677573 )	Lai C.W....Chen J.H.	2013
43	Pulmonary mucinous cystadenocarcinoma: report a case and review of CT findings. ( 23483761 )	Choi Y.A....Lee K.S.	2013
44	Mucinous cystadenocarcinoma arising in an ectopic kidney simulating a retroperitoneal dermoid cyst: a rare tumour presenting as a diagnostic dilemma. ( 23817401 )	Yadav R....Karak A.K.	2013
45	A rare pleural mucinous cystadenocarcinoma mimicking loculated empyema initially: A case report. ( 24604931 )		2013
46	Long-term survival after hand-assisted laparoscopic approach of primary retroperitoneal mucinous cystadenocarcinoma in male: case report and review of literature. ( 23637707 )		2013
47	Pulmonary mucinous cystadenocarcinoma presenting as a pleural mesothelioma. ( 24055913 )		2013
48	Primary mucinous cystadenocarcinoma of the breast with endocervical-like mucinous epithelium. ( 24550753 )		2013
49	Primary retroperitoneal mucinous cystadenocarcinoma in a male patient: a rare case report. ( 24470741 )		2013
50	A case of Krukenberg carcinoma metastasized from colon cancer resembling mucinous cystadenocarcinoma of the ovary. ( 24427362 )		2013

Sources

Genes for Mucinous Cystadenocarcinoma

Genes related to Mucinous Cystadenocarcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	KRT7	Keratin 7	Protein Coding	29.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7543441
2	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	27.44	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17993730
3	KRT20	Keratin 20	Protein Coding	22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7543441
4	SLCO4A1	Solute Carrier Organic Anion Transporter Family Member 4A1	Protein Coding	21.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming	Protein Coding	20.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	FSHR	Follicle Stimulating Hormone Receptor	Protein Coding	20.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	VIM	Vimentin	Protein Coding	17.46	GeneCards inferred via : Publications (show sections)
8	PTPRC	Protein Tyrosine Phosphatase, Receptor Type C	Protein Coding	17.26	GeneCards inferred via : Publications (show sections)
9	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	16.93	Novoseek inferred ⁵⁵	8381375 9852392 1737381
10	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	16.91	GeneCards inferred via : Publications (show sections)

Sources

Variations for Mucinous Cystadenocarcinoma

Sources

Expression for Mucinous Cystadenocarcinoma

Search GEO for disease gene expression data for Mucinous Cystadenocarcinoma.

Sources

Pathways for Mucinous Cystadenocarcinoma

Pathways related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	CLEC7A (Dectin-1) signaling ⁶⁶ Show member pathways Alternative NF-kappaB pathway ¹ CLEC7A/inflammasome pathway ⁶⁶ C-type lectin receptors (CLRs) ⁶⁶	11.91	MUC1 MUC16 MUC2
2	O-linked glycosylation ⁶⁶ Show member pathways O-linked glycosylation of mucins ⁶⁶	11.7	MUC1 MUC16 MUC2
3	Diseases of glycosylation ⁶⁶ Show member pathways Diseases associated with O-glycosylation of proteins ⁶⁶	11.5	MUC1 MUC16 MUC2
4	Cytoskeletal Signaling ⁴	11.41	KRT20 KRT7 MUC1 VIM
5	Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) ⁶⁶ Show member pathways Dectin-2 family ⁶⁶ Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) ⁶⁶ Defective GALNT12 causes colorectal cancer 1 (CRCS1) ⁶⁶ Termination of O-glycan biosynthesis ⁶⁶	11.17	MUC1 MUC16 MUC2

Sources

GO Terms for Mucinous Cystadenocarcinoma

Cellular components related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular exosome	GO:0070062	9.63	KRT7 MUC1 MUC16 PCNA PTPRC VIM
2	intermediate filament	GO:0005882	9.13	KRT20 KRT7 VIM
3	Golgi lumen	GO:0005796	8.8	MUC1 MUC16 MUC2

Biological processes related to Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	intermediate filament organization	GO:0045109	9.16	KRT20 VIM
2	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.13	MUC1 MUC16 MUC2
3	O-glycan processing	GO:0016266	8.8	MUC1 MUC16 MUC2

Sources

Sources for Mucinous Cystadenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia